Opsoclonus myoclonus syndrome

Opsoclonus Myoclonus Syndrome
Classification and external resources
Specialty neurology
ICD-9-CM 379.59
DiseasesDB 31932

Opsoclonus Myoclonus Syndrome (OMS), also known as Opsoclonus-Myoclonus-Ataxia (OMA), is a rare neurological disorder of unknown causes which appears to be the result of an autoimmune process involving the nervous system. It is an extremely rare condition, affecting as few as 1 in 10,000,000 people per year. It affects 2 to 3% of children with neuroblastoma and has been reported to occur with celiac disease.[1][2]

Nomenclature

OMS was first described by Marcel Kinsbourne in 1962.[3] (The term 'Opsoclonus' was coined by Orzechowski in 1913, but it was classically described and associated with neuroblastoma by Kinsbourne). Other names for OMS include:

Signs and symptoms

Symptoms include:

About half of all OMS cases occur in association with neuroblastoma (a cancer of the sympathetic nervous system usually occurring in infants and children).

Diagnosis

Because OMS is so rare and occurs at an average age of 19 months (6 to 36 months), a diagnosis can be slow. Some cases have been misdiagnosed as having been caused by a virus. After a diagnosis of OMS is made, an associated neuroblastoma is discovered in half of cases, with median delay of 3 months.

The interictal EEG pattern is usually normal.[4]

Cause

In children, most cases are associated with neuroblastoma and most of the others are suspected to be associated with a low-grade neuroblastoma that spontaneously regressed before detection. In adults, most cases are associated with breast carcinoma or small-cell lung carcinoma.[5] It is one of the few paraneoplastic (meaning 'indirectly caused by cancer') syndromes that occurs in both children and adults, although the mechanism of immune dysfunction underlying the adult syndrome is probably quite different.

It is hypothesized that a viral infection (perhaps St. Louis encephalitis, Epstein-Barr, Coxsackie B, or enterovirus) causes the remaining cases, though a direct connection has not been proven, or in some cases Lyme disease.[6]

OMS is not generally considered an infectious disease. OMS is not passed on genetically.

Disease course and clinical subtypes

In most cases OMS starts with an acute flare-up of physical symptoms within days or weeks, but some less obvious symptoms such as irritability and malaise may begin weeks or months earlier.

Prognosis

Currently there are no clinically established laboratory investigations available to predict prognosis or therapeutic response.

Tumors in children who develop OMS tend to be more mature, showing favorable histology and absence of n-myc oncogene amplification than similar tumors in children without symptoms of OMS.[7] Involvement of local lymph nodes is common, but these children rarely have distant metastases and their prognosis, in terms of direct morbidity and mortality effects from the tumor, is excellent.[8] The three-year survival rate for children with non-metastatic neuroblastoma and OMS was 100% according to Children’s Cancer Group data (gathered from 675 patients diagnosed between 1980 and 1994); three-year survival in comparable patients with OMS was 77%.[9] Although the symptoms of OMS are typically steroid-responsive and recovery from acute symptoms of OMS can be quite good, children often suffer lifelong neurologic sequelae that impair motor, cognitive, language, and behavioral development.[10][11]

Most children will experience a relapsing form of OMS, though a minority will have a monophasic course and may be more likely to recover without residual deficits.[12] Viral infection may play a role in the reactivation of disease in some patients who had previously experienced remission, possibly by expanding the memory B cell population.[13] Studies have generally asserted that 70-80% of children with OMS will have long-term neurologic, cognitive, behavioral, developmental, and academic impairment. Since neurologic and developmental difficulties have not been reported as a consequence of neuroblastoma or its treatment, it is thought that these are exclusively due to the immune mechanism underlying OMS.[14]

One study came to the conclusion that: "Patients with OMA and neuroblastoma have excellent survival but a high risk of neurologic sequelae. Favourable disease stage correlates with a higher risk for development of neurologic sequelae. The role of anti-neuronal antibodies in late sequelae of OMA needs further clarification".[9]

Another study states that: "Residual behavioral, language, and cognitive problems occurred in the majority".[15]

Treatment

There is no known definitive cure for OMS. However, several drugs have proven to be effective in its treatment.

Some of medication used to treat the symptoms are:

The National Organization for Rare Disorders (NORD) recommends FLAIR therapy consisting of a three-agent protocol involving front-loaded high-dose ACTH, IVIg, and rituximab that was developed by the National Pediatric Myoclonus Center, and has the best-documented outcomes.[17] Almost all patients (80-90%) show improvement with this treatment and the relapse rate appears to be about 20%.[18]

A more detailed summary of current treatment options can be found at Treatment Options

The following medications should probably be avoided:

Research

The National Institute of Neurological Disorders and Stroke (NINDS) conducts and supports research on various movement disorders, including opsoclonus myoclonus. These studies are focused on finding ways to prevent, treat, and cure these disorders, as well as increasing knowledge about them.[19]

References

  1. ↑ Baets, J; Pals, P; Bergmans, B; Foncke, E; Smets, K; Hauman, H; Vanderwegen, L; Cras, P (2006). "Opsoclonus-myoclonus syndrome: A clinicopathological confrontation". Acta neurologica Belgica 106 (3): 142–6. PMID 17091618.
  2. ↑ Deconinck, N; Scaillon, M; Segers, V; Groswasser, J. J.; Dan, B (2006). "Opsoclonus-myoclonus associated with celiac disease". Pediatric Neurology 34 (4): 312–4. doi:10.1016/j.pediatrneurol.2005.08.034. PMID 16638509.
  3. ↑ Kinsbourne M (August 1962). "Myoclonic encephalopathy of infants". J. Neurol. Neurosurg. Psychiatr. 25 (3): 271–6. doi:10.1136/jnnp.25.3.271. PMC 495454. PMID 21610907.
  4. ↑ Ronald, David. Clinical Pediatric Neurology, 3rd edition, 2009, page 205.
  5. ↑
  6. ↑ Cooper R, Khakoo Y, Matthay KK, Lukens JN, Seeger RC, Stram DO, Gerbing RB, Nakagawa A, Shimada H (June 2001). "Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group". Med. Pediatr. Oncol. 36 (6): 623–9. doi:10.1002/mpo.1139. PMID 11344493.
  7. ↑ Gesundheit B, Smith CR, Gerstle JT, Weitzman SS, Chan HS (September 2004). "Ataxia and secretory diarrhea: two unusual paraneoplastic syndromes occurring concurrently in the same patient with ganglioneuroblastoma". J. Pediatr. Hematol. Oncol. 26 (9): 549–52. doi:10.1097/01.mph.0000139414.66455.a4. PMID 15342979.
  8. 1 2 Rudnick E, Khakoo Y, Antunes NL, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, Stram DO, Matthay KK (June 2001). "Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study". Med. Pediatr. Oncol. 36 (6): 612–22. doi:10.1002/mpo.1138. PMID 11344492.
  9. ↑ Mezey LE, Harris CM (April 2002). "Adaptive control of saccades in children with dancing eye syndrome". Ann. N. Y. Acad. Sci. 956: 449–52. doi:10.1111/j.1749-6632.2002.tb02852.x. PMID 11960837.
  10. ↑ Dale RC (May 2003). "Childhood opsoclonus myoclonus". Lancet Neurol 2 (5): 270. doi:10.1016/S1474-4422(03)00374-0. PMID 12849175.
  11. ↑ Mitchell WG, Brumm VL, Azen CG, Patterson KE, Aller SK, Rodriguez J (October 2005). "Longitudinal neurodevelopmental evaluation of children with opsoclonus-ataxia". Pediatrics 116 (4): 901–7. doi:10.1542/peds.2004-2377. PMID 16199699.
  12. ↑ Armstrong MB, Robertson PL, Castle VP (November 2005). "Delayed, recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis". Pediatr. Neurol. 33 (5): 365–7. doi:10.1016/j.pediatrneurol.2005.05.018. PMID 16243225.
  13. ↑ Hayward K, Jeremy RJ, Jenkins S, Barkovich AJ, Gultekin SH, Kramer J, Crittenden M, Matthay KK (October 2001). "Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies". J. Pediatr. 139 (4): 552–9. doi:10.1067/mpd.2001.118200. PMID 11598603.
  14. ↑ Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ (2005). "Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome" (PDF). J Pediatr Oncol Nurs 22 (1): 8–19. doi:10.1177/1043454204272560. PMID 15574722.
  15. ↑ Pranzatelli MR, Tate ED, Travelstead AL, Longee D (January 2005). "Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome". Pediatrics 115 (1): e115–9. doi:10.1542/peds.2004-0845. PMID 15601813.
  16. ↑ "Effect of Increased Immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS)". ResearchGate. Retrieved 2015-09-04.
  17. ↑ "Opsoclonus-Myoclonus Syndrome - NORD (National Organization for Rare Disorders)". Retrieved 2015-09-04.
  18. ↑ "NINDS Opsoclonus Myoclonus Information Page". National Institute of Neurological Disorders and Stroke. Retrieved October 9, 2011.

Further reading

  • Mitchell WG, Davalos-Gonzalez Y, Brumm VL, Aller SK, Burger E, Turkel SB, Borchert MS, Hollar S, Padilla S (January 2002). "Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae". Pediatrics 109 (1): 86–98. PMID 11773546. 
  • Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Moticka EJ, Franz DN, Nigro MA, Parke JT, Stumpf DA, Verhulst SJ (May 2004). "B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes". Neurology 62 (9): 1526–32. doi:10.1212/WNL.62.9.1526. PMID 15136676. 
  • Rothenberg AB, Berdon WE, D'Angio GJ, Yamashiro DJ, Cowles RA (July 2009). "The association between neuroblastoma and opsoclonus-myoclonus syndrome: a historical review". Pediatr Radiol 39 (7): 723–6. doi:10.1007/s00247-009-1282-x. PMID 19430769. 

External links


This article is issued from Wikipedia - version of the Saturday, April 16, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.